OncoSil Medical (ASX:OSL) has announced encouraging preliminary results from its PANCOSIL Phase 1–2 Investigator Initiated Study, marking a potential breakthrough in the treatment of locally advanced pancreatic cancer (LAPC).
Presented at the CIRSE 2025 Congress in Barcelona, the study is the first in the world to evaluate delivery of the OncoSil device via CT-guided percutaneous injection, which is a minimally invasive technique that could expand access to the therapy worldwide.
Key findings from the study of 20 patients include that no procedure-related deaths were reported. Two patients (10 per cent) experienced Grade 3 adverse events, both of whom recovered. The procedure achieved a 90 per cent technical success rate, with investigators noting it can be performed while patients remain conscious, reducing procedure time and recovery. Three patients (15 per cent) showed partial tumour response in addition to chemotherapy benefits, with median overall survival reaching 20.6 months, significantly higher than the historical LAPC benchmark of 13 months.
Professor Martijn Meijerink, Interventional Oncologist at Amsterdam UMC, said, “The PANCOSIL study shows that CT-guided implantation of the OncoSil™ device is safe and feasible, while offering encouraging signals of clinical benefit. This approach enables interventional radiologists to deliver treatment with precision and reproducibility.”
OncoSil CEO and Managing Director, Nigel Lange, highlighted the impact of the results. “These findings strengthen our clinical evidence base and mark another step forward in our mission to transform outcomes for patients with pancreatic cancer. Importantly, the percutaneous approach broadens the pool of treating clinicians, increasing the potential reach of OncoSil.”
The company said it plans to pursue additional regulatory approvals in the second half of the financial year 2026, initially targeting label expansion in the European Union.